SRx Health Solutions Inc.

SRx Health Solutions Inc.

SRXH
SRx Health Solutions Inc.US flagNew York Stock Exchange American
0.12
USD
-0.01
- -
4.05MMarket Cap
SRx Health Solutions Inc.
SRXH
(New York Stock Exchange American)

Recent

price

0.12

P/E

ratio

- -

div

yld

- -

ROIC.AI

2024
2025
FRC
- -
0.26
Revenue per Share
-3.01
-1.81
Basic EPS, GAAP
-0.1
-0.41
Free Cash Flow per Basic Share
- -
- -
Dividend per Share
-4.9
-0.92
Book Value per Share
-4.34
0.02
Tangible Book Value per Share
14
25
Basic Weighted Avg Shares
- -
7
Sales/Revenue/Turnover
- -
-174.56
Operating Margin (%)
4
- -
Depreciation Expense
-43
-45
Net Income, GAAP
- -
- -
Effective Tax Rate (%)
- -
-688.8
Profit Margin (%)
-68
5
Working Capital
6
4
LT Debt
-55
- -
Total Equity
- -
- -
Return on Invested Capital (%)
- -
- -
Return on Capital (%)
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-100.74%
Free Cash Flow
- -
- -
591.41%
Net Income, GAAP
- -
- -
4.53%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
7
-35
- -
7
2026
3
3
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-3.01
2025
-0.28
-0.07
- -
- -
-1.81
2026
-0.09
-0.02
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
SRx Health Solutions Inc. SRx Health Solutions Inc. (SRXH) operates as an integrated healthcare services provider in the specialty pharmacy and pet health and wellness sectors across Canada and the United States. The company offers a comprehensive range of services including specialty pharmacy for complex and chronic disease management; infusion clinics and nursing for biologics, iron therapy, and injectable training; patient support programs; wholesale and pharmaceutical distribution from its Health Canada-accredited facility in Mississauga, Ontario; clinical trials sites; compounding services; retail pharmacy operations; travel health consultations with vaccinations and preventive medications; and pet products such as dry food, wet food, treats, supplements, dental products, chews, and vegan options under the Halo brand. With a national footprint in Canada encompassing 29 specialty pharmacies, 40 infusion clinics and injection sites, four clinical trials sites, and an allied health team, SRx Health Solutions serves patients, hospitals, physicians, pharmaceutical manufacturers, and retailers targeting chronic, rare diseases, and everyday healthcare needs. Founded in 2013 and headquartered in Toronto, Canada, the company expanded significantly through its April 2025 business combination with Better Choice Company Inc., which resulted in a name change from Better Choice to SRx Health Solutions Inc., a stock split, rebranding, and NYSE American listing under ticker SRXH; this merger created a global health and wellness entity with projected 2025 revenues exceeding $270 million and positioned SRx securityholders to own approximately 85% of the combined company on a fully diluted basis.

Company News

APIChat
  • SRx Health Solutions Invests in Uber Technologies, Inc. and Provides Shareholders with Portfolio Update

  • SRx Health Solutions and EMJX Invest in Recent IPO and Commercial-Stage Pharmaceutical Company of Psychedelics, Optimi Health Corp. (OPTH)

  • SRx Health Solutions Announces Board Approval to Dividend 75% of Profits from Investment in Astro Investment XVII, an Affiliate of Astro Capital and SPV with Investments in SpaceX and Other Artificial Intelligence and Space Companies

  • SRx Health Solutions Announces Fiscal Second Quarter 2026 Results for Quarter Ended March 31, 2026

  • SRx Health Solutions Invests in Astro Investment XVII, an Affiliate of Astro Capital and SPV with Investments in SpaceX and Other Artificial Intelligence and Space Companies

  • SRx Health Solutions Invests in Astro Investment XVII, an Affiliate of Astro Capital

  • SRx Health Solutions and EMJX Issue Letter to Shareholders from Eric M. Jackson

  • SRx Health Solutions Acquires Shares of Compass Inc. and Increases Investment in Opendoor Technologies Inc.

  • SRx Health Solutions Hedges Decentralized Finance (DeFi) Portfolio with Investment in Gold and Reduces its Emerging Market Hedge

  • SRx Health Solutions Hedges Investments in Cryptocurrency and Emerging Markets for Volatility Protection

  • SRx Health Solutions Increases Ownership of Opendoor Technologies by 30% and is Now Net Long Cryptocurrency Holdings

  • SRx Health Solutions Announces Receipt of Warning Letter from NYSE American

  • SRX Health Solutions Inc. Announces Fiscal First Quarter 2026 Results for Quarter Ended December 31, 2025

  • SRx Health Solutions Redeems Series A Preferred Stock and Cancels Approximately 125,000,000 Shares of Common Stock, Improving Balance Sheet Flexibility for Investment in M&A or Return of Capital to Shareholders

  • SRx Health Solutions Launches EventHorizonIQ, a Public Ledger of AI-Generated Financial Market Instability Signals

  • SRx Health Solutions Significantly Reduces Short Position of Cryptocurrency Portfolio Amidst Current Market Volatility

  • SRx Health Solutions Allocates Further Capital to its Digital Asset Treasury Hedging Strategy, Bringing Total Allocation to $18 Million

  • SRx Health Solutions Invests in Common Stock of Opendoor Technologies

  • EMJX CEO Eric Jackson to Host Fireside Chat on EMJX Treasury OS Strategy and Governance on January 22nd

  • SRx Health Solutions Regains Compliance with NYSE